Funding
← Back to your selection

Sofinnova Partners

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jul 27, 2026
Rounds participated in
2
Confirmed lead rounds
0
All roles disclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$53.6M
2 disclosed · full round size, not this investor’s share

By stage

Series B1
Undisclosed1

By primary sector

Biotech2

By country

Sweden1
United Kingdom1

Rounds

2 in this selection
EnginZyme

EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes.

SEK 75MEquity round
Participant
Mironid

Mironid develops small-molecule medicines for inherited kidney disease, with a lead programme targeting autosomal dominant polycystic kidney disease.

$46MSeries B
Participant